A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease.
The purpose of this study is to evaluate the clinical efficacy, clinical and endoscopic efficacy and safety of guselkumab in participants with Crohn’s disease.
Principal Investigator:
Point of Contact: